Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MESOBLAST LTD Board/Management Information 2022

Apr 5, 2022

31658_rns_2022-04-05_3d73d60f-c5f8-42f1-9910-f24d75d320b8.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

APPOINTMENT OF JOINT COMPANY SECRETARY

Melbourne, Australia; April 6 and New York, USA; April 6, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Paul Hughes has been appointed as Joint Company Secretary of Mesoblast Limited, joining the existing Company Secretary, Ms Niva Sivakumar. Mr Hughes and Ms Sivakumar are jointly responsible for the Company Secretary role for Mesoblast and are the persons responsible under Listing Rule 12.6 for communications with the ASX.

Ms Sivakumar was appointed as Company Secretary of Mesoblast Limited in October 2019. Mr Hughes began working with Mesoblast in February 2019 following a long career as an investment banker and corporate advisor. He has served as Mesoblast’s Global Head of Corporate Communications since December 2020.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors Media Paul Hughes Sumit Media T: +61 3 9639 6036 Grant Titmus E: [email protected] T: +61 419 388 161 E: [email protected]

Rubenstein Nadine Woloshin T: +1 917-699-9456 E: [email protected]

==> picture [595 x 92] intentionally omitted <==